360Dx

NIPT Laboratories Don't Follow All ACMG Recommendations for Reporting, Patient Education

Apr 03, 2019

NEW YORK (GenomeWeb) – Commercial laboratories offering cell-free DNA-based noninvasive prenatal testing (NIPT) in the US do not follow all recommendations put forward by the American College of Medical Genetics and Genomics in 2016, a new study has found. According to the authors, this may lead to confusion and improper counseling.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

NIPT Laboratories Don't Follow All ACMG Recommendations for Reporting, Patient Education

To read the full story....

Breaking News

Guardant Health CDx Wins FDA Approval for First Liquid Biopsy NGS Tumor Profiling Assay

FDA Revokes Emergency Use Authorization for Autobio Diagnostics SARS-CoV-2 Serology Test

Wide Variation in Genomic Testing Utilization Across US, Report Finds

Natera Files Additional Patent Infringement Lawsuit Against ArcherDx

Meridian Bioscience Fiscal Q3 Revenues Soar 75 Percent on COVID-19-Related Life Sciences Growth

Tangen Biosciences Closes $12.2M Series B Financing

Featured White Papers

Demystifying COVID-19 Antibody Testing

COVID-19 Wastewater-Based Epidemiology: Methods and Insights for SARS-CoV-2 Community Surveillance

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

What's Popular?

Germany Starts Going After Coronavirus Cases With Free Testing for Returning Travelers

Luminex Responds to FDA Warning Letter While Ramping SARS-CoV-2 Test Manufacturing

NHS Will Roll Out COVID-19 Tests From DnaNudge, Oxford Nanopore Across UK

Illumina Sees Expanding Sequencing Market in COVID-19 Response, Despite Short-Term Woes

Vela Diagnostics, Capstone Healthcare Get FDA Emergency Use Authorization for Coronavirus Tests

Sponsorships